Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy of etanercept with usual disease-modifying anti-rheumatic drug (DMARD) therapy in the treatment of moderate to severe rheumatoid arthritis (RA) over 16 weeks in the Asia Pacific region.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Etanercept; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine

Criteria

Inclusion Criteria:

• Diagnosis of RA

• Currently receiving an adequate dose of methotrexate (MTX) for treatment of RA

• Active RA at time of screening and baseline

Exclusion Criteria:

• Previous or current treatment with etanercept (ETN), other tumor necrosis factor-alpha inhibitors, or other biologic agents

• Concurrent treatment with a DMARD, other than MTX, at screening

• Receipt of any DMARD, other than MTX, within 3 months before screening